Forget The Death-Star Anti-Mosquito Lasers, Here's How Nathan Myhrvold Can Help Tackle Malaria — And Improve His Image

Patents

from the really-doing-good dept

Nathan Myhrvold is trying to rustle up a little positive PR for Intellectual Ventures (IV) by appointing a VP of Global Good (although it’s hard to see how anyone lumbered with such a daft job title is going to be taken seriously anywhere.) You can gauge just how touchy Myhrvold is on this topic by his rather waspish response to some commentary on that move.

As Techdirt reported, Myhrvold came up with what he obviously thinks is a winning riposte whenever people criticize IV’s business model based on industrial-scale patent trollery. He asks them: “How big is your malaria project?” His point being that IV does does have a malaria project, so this somehow makes up for all the bad stuff it does. There’s only one slight problem: that project offers little more than fantasy solutions. For example, here are some details from Intellectual Ventures Lab’s malaria page about a cool-sounding “photonic fence” designed to keep out mosquitoes:

However impressive all that technology might be, there’s the obvious problem that mosquitoes could just fly over these “photonic fences”. Perhaps conscious of this flaw, the page describes several other equally ingenious — and equally impractical — approaches to tackling malaria including the use of magnets to make mosquitoes explode and an “engineered blood substitute” to draw them away from humans (also useful for regions plagued by vampires, presumably.)

This impracticality rather undermines Myhrvold’s taunting of lesser mortals that don’t have their own malaria project, since his lab projects seem unlikely to make any significant contribution to combatting malaria in the short term, if ever. Clearly, to tackle malaria in real-life situations, what is needed is not some super high-tech approach that looks good in TED talks, but something rather more simple and effective — something like this, perhaps:

Unlike potentially blinding lasers, the new compound is claimed to be safe, with no adverse side effects. Of course, lots of clinical tests still need to be run to establish that and its efficacity. Then, a way to manufacture and distribute the drug to malaria victims will need to be found. The worry has to be that traditional drug companies won’t be interested in helping here, since the drug must be sold cheaply if it is to reach the millions of people most affected by malaria, and that means few if any profits — not something pharma companies are happy with.

So here’s a suggestion. If Myhrvold really wants to burnish the image of Intellectual Ventures through philanthropic activities, he should forget about appointing his VP of Global Good, and drop his fun but useless malaria program. Instead, he and his company should offer to pay all the costs for carrying out the clinical tests of this new anti-malarial drug, and for setting up a large-scale manufacturing program sufficient to treat everyone in the world that has the disease, or is at risk from it. Helping to circumvent problems caused by drug companies’ obsession with patents and exorbitant profits would be a truly fitting way to atone for the sins of Intellectual Ventures.

Follow me @glynmoody on Twitter or identi.ca, and on Google+

Filed Under: drugs, malaria, mosquitoes, patents
Companies: intellectual ventures